- Psychiatric Times Vol 28 No 6
- Volume 28
- Issue 6
Avoiding SRI Discontinuation Syndrome
What’s the best way to avoid the paresthesias that can occur in some patients who discontinue SSRI or serotonin-norepinephrine reuptake inhibitor (SNRI) therapy?
Q: What’s the best way to avoid the paresthesias that can occur in some patients who discontinue SSRI or serotonin-norepinephrine reuptake inhibitor (SNRI) therapy? Some of my patients describe “flashes through head, body, or limbs” when discontinuing these medications. How can this be prevented-and managed?
A: These symptoms are consistent with serotonin reuptake inhibitor (SRI) discontinuation syndrome and they can occur in patients who are withdrawing from therapy with an SSRI or an SNRI.
Many different classes of CNS drugs can initiate adaptive mechanisms in the brain (eg, receptor down- or up-regulation) with a sufficient duration of treatment. Usually, patients have to have been treated for weeks (and sometimes longer) before such adaptive changes occur. These changes can set the stage for withdrawal symptoms if the drug is cleared faster than the brain can re-equilibrate. For this reason, drugs with shorter half-lives are associated with withdrawal symptoms of greater frequency and/or severity.
The symptoms of SRI discontinuation syndrome can be remembered by the mnemonic FLUSH. F is for flu-like symptoms, L for light-headedness, U for uneasiness (mainly depressive and anxiety symptoms), S for sensory or sleep disturbance, and H for headache. The sensory disturbances include paresthesias, described in the question.
As with all CNS drugs capable of causing adaptive changes in the brain, the first goal is to prevent withdrawal syndromes. Whenever possible, the medication should be tapered rather than abruptly discontinued. When a short half-life makes tapering difficult or when the symptoms occur despite tapering, an alternative is to switch to a drug with a long half-life in the same class and then taper it. With SSRIs and SNRIs, this could mean switching to fluoxetine, which has a functionally long half-life-particularly when the half-life of its active metabolite, norfluoxetine is also considered. Fluoxetine can then be discontinued because it essentially tapers itself.
Of course, there are other reasons (eg, peripheral neuropathy) why patients might have the symptoms described. It is always important to consider other possibilities when evaluating patients and planning their care.
Articles in this issue
over 14 years ago
Feeling Socially Safeover 14 years ago
Drs McGlashan and Woods Respond to Dr Feinbergover 14 years ago
Obama Drug Misuse Strategy Targets Physician Educationover 14 years ago
Alfred M. Freedman, MD, 1917-2011over 14 years ago
Is It Treatment-Refractory Schizophrenia . . . And if It Is?over 14 years ago
Are We Training Psychiatrists to Provide Only Medication Management?over 14 years ago
Effects of Early Parental Depressionover 14 years ago
Are Some Patients Trying to “Medicalize” Chronic Fatigue?Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.